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Infertility and menstrual irregularities are among the disorders linked to 
polycystic ovary syndrome, a disorder affecting 3 to 7 percent of all 
women in their reproductive years. Researchers at BUSM are investigat-
ing causes and experimenting with treatments. See story on page 4. 
BUSM researcher Judith L. Vaitukaitis, M.D., left, and research technician Valerie Head 
investigate polycystic ovary syndrome. See page 4. (Photo by Bradford F. Herzog) 
Investigators at BUSM find concentration 
improved with neuropeptide injections 
Nearly everyone experiences occa-
sional concentration lapses, from el-
derly people filling out tax forms to 
air traffic controllers guiding hun-
dreds of planes to safe landings. Yet 
concentration is a key factor, if 
sometimes an elusive one, in assur-
ing successful completion of a task. 
A treatment that improves concen-
tration may someday be made avail-
able to virtually anybody as a result 
of research being conducted by Lyie 
Miller, Ph.D., a professor of psychia-
try (psychology) and chairman of the 
Department of Biobehavioral Sci-
ences at Boston University School of 
Medicine. Miller and his associates 
have been working with a neuropep-
tide fragment which, when injected 
into the body, allows people to con-
centrate better for longer periods of 
time. Enhanced concentration in turn 
permits the subjects to learn better, 
remember better and generally per-
form at higher productivity levels. 
"This substance influences your at-
tention span by decreasing the 
continued on page 5 
BUSM is among 
world's key centers 
for the study of 
amyloid disease 
Amyloidosis is a disorder widespread 
in man and animals. 
It is characterized by the buildup of 
a fibrous protein in a variety of tis-
sues and organs throughout the 
body. 
Medically, this buildup can have 
devastating consequences, the result 
of the physical presence of the fi-
brous substance. Such organs as the 
liver may be enlarged by several 
times their normal size. Victims of 
the condition may be subjected to an 
extended period of pain and incapa-
citation. And, for most victims, the ul-
timate outcome is death. 
Among the leading experts in the 
world on the ailment are the mem-
bers of a team of researchers at 
Boston University School of Medi-
cine. The team is headed by Alan S. 
Cohen, M.D., the Conrad Wessel-
hoeft Professor of Medicine, director 
of the Arthritis Section and head of 
the Multipurpose Arthritis Center at 
BUSM. Cohen also is chief of medi-
cine and director of the Thorndike 
Memorial Clinical Research Labora-
tory at Boston City Hospital. 
The Multipurpose Arthritis Center, 
which operates in close cooperation 
with University Hospital in Boston, 
BCH and the Boston Veterans Ad-
ministration Medical Center, is a 
continued on page 2 
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Amyloid disease... 
continued from page 1 
major component of the Boston 
University Arthritis Center. The 
Multipurpose Arthritis Center has at-
tained a national reputation for re-
search in lupus, amyloidosis, infec-
tious arthritis, bursitis, rheumatoid 
arthritis, inflammation and other mus-
culoskeletal disorders. The Center 
was named one of 15 Multipurpose 
Arthritis Centers in the country fol-
lowing passage of the National Ar-
thritis Act in 1974. Much of the finan-
cial support for research at the 
Center comes from the National In-
stitutes of Health. 
According to Cohen, the identifica-
tion of amyloid as a separate dis-
ease—or more accurately, as a 
group of closely related diseases— 
did not occur until the late 1950s. 
"In the past," said Cohen, "amyloid 
was regarded as sort of a potpourri 
of disorders. But in 1959, we de-
scribed amyloid as a unique fibril, 
which we then isolated." 
Not only have Cohen and his as-
sociates identified the substance and 
the disease, they also have been 
major contributors to the evolving un-
derstanding of the ailment—which in-
cludes the discovery that while still 
considered rare, the disease is by no 
means as unusual as originally 
thought. 
Cohen noted, for example, that 
one form of the disease is "a major 
complication of any chronic inflam-
matory disease, such as rheumatoid 
arthritis, and of any chronic infectious 
disease, such as tuberculosis or os-
teomyelitis." 
This form of amyloid disease like-
wise used to be a serious problem 
for paraplegics because of the sores 
and infections they frequently devel-
oped before methods of care were 
improved, according to Martha Skin-
ner, M.D., an associate professor of 
medicine and director of research for 
BUSM's Arthritis Section. 
In addition, there is an extremely 
rare form of amyloid that is geneti-
cally based and runs in families. 
This form usually involves amyloid 
buildup in the body's nervous sys-
tem. Many families from all over the 
United States afflicted with this form 
of the disease have been referred to 
BUSM for study and treatment. 
Yet another form has neither the 
genetic nor the inflammation/infection 
tie-in. Instead, this form, called pri-
mary amyloid, apparently develops 
on its own from causes that relate to 
abnormalities in immune globulins. 
Most intriguing yet, there is strong 
evidence of a connection between 
amyloid and aging, said Cohen. 
"As we get older, virtually all of us 
have small amounts of amyloid 
plaques (deposits) in our brains," 
said Cohen. The deposits are espe-
cially frequent in victims of Alzhei-
mer's disease, an ailment wide-
spread among the elderly whose 
symptoms include slurred speech, 
loss of memory and diminished con-
trol over bodily functions. 
It is not yet clear, said Cohen, 
whether the elderly with amyloid 
Alan S. Cohen, M.D., at left, has studied 
amyloid disease for 22 years. The photo 
above shows amyioid buildup in human 
tissue, magnified 80,000 times. Note the long, 
interwoven fibrils that are characteristic of 
amyloid. (Photo at left by Bradford F. Herzog; 
photo above previously published in the 
Journal of Cell Biology) 
plaques actually are suffering from 
amyloidosis, or perhaps whether the 
amyloid may play some role in bring-
ing on Alzheimer's disease. 
Recently, however, a finding that 
may shed more light on the nature 
and role of the amyloid buildup in the 
brains of the elderly has been made 
by Tsuranobu Shirahama, M.D., 
Ph.D., an associate research profes-
sor of medicine, and other members 
of the BUSM group. They identified a 
normal component of the blood, 
prealbumin, in these senile plaques. 
The investigation of the connection 
between aging and amyloid is but 
one of literally dozens of aspects of 
amyloid disease currently under 
scrutiny at BUSM. Another, of critical 
importance in aiding the victims of 
amyloid, is improving methods of di-
agnosis. 
The problems connected with diag-
nosis have until recently been one of 
the most frustrating aspects of amy-
loid disease, said Alan Rubinow, 
M.D., an assistant professor of medi-
cine at BUSM. 
Working with patients referred from 
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across the nation to the Thorndike 
Memorial Laboratory, and on occa-
sion from overseas as well, the 
BUSM group has developed new 
methods of diagnosis that avoid the 
traditional need to remove tissues 
from inside the body for testing. 
"Roughly 90 percent of amyloid 
cases involve the heart," said Rubi-
now. "In fact, many amyloid victims 
die of cardiac arrest. 
"A number of years ago," he con-
tinued, "we did a study in which we 
tested a few patients with a bone 
scan. This is where you inject ra-
dioactive isotopes that seek calcium 
into the body, and they will light up 
the bone." 
Although the bone scan was de-
veloped mainly to probe bone di-
seases like osteomyelitis, Rubinow 
and his associates found that when 
the isotopes were injected into a pa-
tient suspected of having amyloid, 
"their hearts lit up. It turned out to be 
a very sensitive test for cardiac amy-
loid." 
The reason why it works is not 
wholly clear, said Rubinow, though 
other experiments have shown that 
calcium buildup occurs in amyloid 
deposits. But in any case, the finding 
has made possible a low-cost, read-
ily accessible method for diagnosing 
most amyloid cases. 
The BUSM group also is seeking 
further information about what so far 
is the best therapy for amyloid—the 
administration of the drug colchicine. 
This drug, said Rubinow, has long 
been used in treating gout and also 
a rare genetic disease that afflicts 
families in various countries border-
ing the Mediterranean Sea. 
By one of those serendipitous de-
velopments that sometimes occurs in 
medicine, doctors in Israel treating 
victims of this ailment, familial Medi-
terranean fever, found that colchicine 
virtually eliminates their chances of 
also contracting amyloid disease. 
Previously, more than half of the fe-
ver victims also had been developing 
amyloid. 
To explore further colchicine's ef-
fectiveness, said Rubinow, "We set 
up a therapeutic study using colchi-
cine in a group of 86 patients who 
already had amyloid. We found that 
the survival time in primary amyloid 
increased from about 8 to 24 
months." 
The study is not definitive because 
there was no matching control group 
of patients who were denied the 
drug. Cohen, however, said it is diffi-
cult to justify such a controlled study 
"It's a common drug and it has vir-
tually no side effects," he explained. 
"How can you morally and ethically 
not put your patients on it when you 
have, for example, siblings in their 
'30s with an expected life span of 
only 10 years? Can you treat one 
and not the other?" 
The BUSM group is convinced col-
chicine is useful, though, and more 
research on how and when to use 
the drug is underway, according to 
Rubinow. 
Meanwhile, there is other ongoing 
research aimed not so much at deal-
ing with the problems of diagnosing 
and treating amyloid disease as with 
gaining an understanding of its fun-
damental causes. 
One subject under scrutiny is the 
role of a substance in the blood 
called serum amyloid A. This sub-
stance, SAA for short, has been 
given this designation because it 
must build up in the blood before the 
form of amyloid associated with in-
flammation (known as amyloid A, or 
AA) can develop. 
Everyone gets some SAA in their 
blood in response to inflammation, 
said Jean Sipe, Ph.D., associate re-
search professor of medicine and 
biochemistry. Moreover, she said, 
animal experiments indicate that 
SAA must play a critical role in re-
sponding to injuries or infections. 
"Everyone makes SAA every time 
they have an injury or an infection," 
said Sipe, "but very few develop 
amyloid disease." The BUSM group, 
therefore, is exploring what causes 
SAA to turn into amyloid. 
One avenue of exploration, said 
Sipe, centers around the role of an-
other substance in the blood called 
interleukin 1. 
This substance, like SAA, is a nor-
mal product of inflammation. Experi-
ments with mice, said Sipe, have 
shown that injuries stimulate the im-
mune system to make the sub-
stance. Interleukin 1, acting very 
much like a messenger from what-
ever corner of the body the injury 
may have occurred in, then travels 
through the blood to the liver, where 
it stimulates that organ to make SAA. 
Sipe is looking into a host of ques-
tions surrounding interleukin 1, in-
cluding the possibility that it some-
how may influence the type of SAA 
produced, and thereby help deter-
mine the likelihood that an inflamma-
tion will lead to amyloid disease. 
The basic research on amyloid, it 
should be noted, clearly has the po-
tential for illuminating many other as-
pects of bodily functions in addition 
to how and why some people get 
amyloid disease. Sipe pointed out, 
for example, that the existence of 
SAA, which is a basic part of the 
body's response to injury or infection, 
was unknown until investigators, in-
cluding Sipe and her colleagues, be-
gan exploring amyloid. 
Even if there were no general ap-
plications of the knowledge they are 
acquiring, however, there appears to 
be an ever-growing motivation to ex-
plore amyloid disease in its own 
right. As Skinner noted, "It's a fairly 
rare disease, but we're learning that 
the more you look into the disease, 
the more you find." 
— Richard P. Anthony 
Suggested Further Readings 
1. Cohen, A.S. and Calkins, E.: Electron mi-
croscopic observations of a fibrous compo-
nent in amyloid of diverse origins. Nature 
183: 1202, 1959. 
2. Cohen, A.S. Amyloidosis. New Eng J Med. 
277: 522, 754, 628, 1967. 
3. Skinner, M. et al: Amyloid fibril protein re-
lated to immunoglobulin lambda chains. J 
Immunol. 114: 1433, 1975. 
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BUSM researchers seek causes, cure 
for polycystic ovary syndrome 
Polycystic ovary syndrome is a com-
mon endocrinologic disorder affecting 
3 to 7 percent of all women in their 
reproductive years. Women having 
the syndrome frequently have men-
strual irregularities, including amen-
orrhea; infertility; abnormal hair 
growth on the face, chest or abdo-
men; acne; severe intermittent ab-
dominal pain; and/or obesity. 
While the specific cause of this 
physically and psychologically dam-
aging disorder is not known, it is 
known to be related to excess pro-
duction of such male hormones as 
androgen and altered secretion of 
the pituitary hormones—prolactin and 
gonadotropin, according to Judith L. 
Vaitukaitis, M.D., a professor of med-
icine and physiology at Boston Uni-
versity School of Medicine and head 
of the Section of Endocrinology and 
Metabolism at BUSM. Vaitukaitis has 
studied this and other serious endo-
crinologic disorders for 14 years. 
"Up until this time, polycystic ovary 
syndrome has been treated hormon-
ally with oral contraceptives to sup-
press the pituitary secretion of go-
nadotropins and with steroids to 
suppress ovarian and adrenal hor-
mone secretion. Now we have found 
that some women can be success-
fully treated with a nonhormonal sub-
stance that simulates a chemical in 
the brain that controls pituitary secre-
tion related to the syndrome," said 
Vaitukaitis, who also is program di-
rector of the University's 14-year-old 
General Clinical Research Center lo-
cated at Boston City Hospital. The 
facility, which recently was awarded 
a five-year competitive renewal grant 
from the National Institutes of Health, 
serves as an adjunctive inpatient 
clinical research facility for ongoing 
research on reproductive neuroendo-
crinology, amyloidosis, hypertension 
and other disorders. 
Vaitukaitis, who collaborates with 
Jon Pehrson, M.D., an assistant pro-
fessor of medicine designate at 
BUSM, on her studies, has found 
that two hormones secreted by the 
pituitary gland that stimulate gonado-
tropins, called follicle stimulating hor-
mones (FSH) and luteinizing hor-
mones (LH), are secreted in an 
abnormal pattern. "The result is a 
'Catch 22' situation—the excess 
male hormone secreted by the ova-
ries and possibly adrenal glands in 
turn further alters control of gonado-
tropin secretion," she explained. As a 
result, the follicles in the ovary are 
stimulated in the wrong sequence 
and too much male hormone is pro-
duced. It also may result in the for-
mation of small pockets of fluid 
within the ovary called cysts that can 
interfere with the normal functioning 
of the reproductive gland. 
Judith L. Vaitukaitis, M.D., reviews a patient's 
data with Anita Petrafesa, R.N., B.S., head 
nurse at BUSM's General Clinical Research 
Center. (Photo by Bradford F. Herzog) 
She also has found that the hy-
pothalmus, the area of the brain that 
controls the pituitary gland, contains 
several clusters of nerve cells or nu-
clei that secrete chemical transmit-
ters affecting the pituitary gland's se-
cretion of FSH and LH. One of the 
substances is called dopamine, a 
small molecular messenger that prin-
cipally affects the pituitary gland's 
secretion of the hormones prolactin 
and LH. 
In a study of 33 women with poly-
cystic ovary syndrome, Vaitukaitis 
has found that one-third had small 
but significant elevations of prolactin 
levels in their blood. Since the secre-
tion of gonadotropins and prolactin is 
influenced by dopamine in normal 
women, Vaitukaitis is studying 
whether there is abnormal dopamin-
ergic control of these hormones in 
patients having the syndrome. 
"Our studies reveal that patients 
with polycystic ovary syndrome have 
an abnormally large amount of LH 
and prolactin stored in their pituitary 
glands," she said. "We also have 
identified for the first time evidence 
of altered dopaminergic control of 
gonadotropin and prolactin secretion 
in these women. We don't know if it's 
a primary or a secondary defect." 
These observations suggested that 
an alternative to oral contraceptives 
is feasible for treatment of patients 
with polycystic ovary syndrome. 
Bromocriptine (Parlodel), a drug that 
works like dopamine, was found to 
be an effective form of therapy for 
many patients with the syndrome. 
"Our preliminary studies of treating 
women with the disorder (with brom-
ocriptine) strongly suggest that nor-
mal gonadotropin and prolactin se-
cretion can be restored in these 
women and cyclic menstrual periods 
reinstituted," said Vaitukaitis, who is 
seeking new funds to continue her 
research. 
The researchers further have 
found cases in which some women 
who have polycystic ovary syndrome 
have excess androgen production, 
but do not have altered levels of LH 
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and FSH hormones. 
"We're trying to understand why 
these women have the same bio-
chemical defects," she said. "The 
question is: Is the secreted hormone 
altered biologically or is there an-
other pituitary hormone yet to be 
identified that affects ovarian and 
adrenal androgen production?" 
To get a handle on how glycopro-
teins work, she is conducting rat 
studies, investigating how hormones 
work at the cellular level. "The 
dogma has been that glycoprotein 
hormones, including gonadotropins, 
only work at the cell surface. Only in 
recent years have we realized that 
these hormones are internalized and 
remain biologically active within the 
cells," she said. "We don't know what 
the significance of this information 
is—it's a new observation." 
Vaitukaitis also is conducting re-
search on tumor secretion of another 
gonadotropin, chorionic gonadotropin 
(CG). That hormone is composed of 
two subunits that may be differen-
tially secreted among some patients 
with CG-secreting tumors. With new, 
more effective forms of chemother-
apy for men having testicular tumors 
that secrete CG, attempts are being 
made to correlate the pattern of CG 
and its subunits found in biologic 
fluids and tumor tissues with the can-
cer patients' responses to chemo-
therapy. 
—Marjorie H. Dwyer 
Suggested Further Readings 
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Neuropeptides... 
continued from page 1 
threshold for excitation of the brain. It 
makes it easier for your brain to 
work," said Miller. 
Neuropeptides are peptides 
(chemical compounds in the body 
containing amino acids) that influ-
ence the nervous system. They are 
formed as a result of chemical 
changes in proteins in the human 
body and also can be made syntheti-
cally in the laboratory. Their behav-
ioral effect comes from the fact that 
they alter nerve cell membranes, en-
abling the nerve cells to communi-
cate with each other more easily. 
Research to discover just how 
much influence neuropeptides have 
on human behavior is still in its early 
stages. "Medical science has just re-
cently become aware of the impor-
tance of neuropeptides and of the 
significant influence they have on 
brain function and human behavior," 
said Miller. 
The attention-boosting neuropep-
tide fragment that Miller has been 
working with is called MSH/AGTH 4-
10. It is found in both melanocyte-
stimulating hormone (MSH) and ad-
renocorticotropic hormone (ACTH), 
and is made up of the fourth to tenth 
amino acids in these hormone 
chains. 
At this time, a single injection of 
MSH/AGTH 4-10 that produces a 
brief improvement in concentration is 
very expensive and the longterm ef-
fects of repeated use of the neuro-
peptide on the human body are not 
known. However, in time, this "anti-
boredom" substance could help el-
derly persons to remember more 
easily, mentally retarded persons to 
learn more quickly and surgeons to 
operate more carefully. Miller said. 
Miller, who came to BUSM in 
1978, stressed that although MSH/ 
AGTH 4-10 has a behavioral effect 
similar to some amphetamines, the 
substance is not merely another am-
phetamine. "Amphetamines raise 
your whole level of functioning. This 
particular substance only increases 
the activity of the higher centers. An 
amphetamine pushes you way up 
and you're really jittery and you're 
higher than you've ever been. All 
MSH/AGTH 4-10 does is take you up 
to your normal high level of function-
ing, whatever that happens to be, 
and it keeps you there for a longer 
period of time," he said. 
In the late 1960s, before the MSH/ 
AGTH 4-10 fragment was readily 
available. Miller began studying 
AGTH and MSH and their effects on 
behavior. In 1969, along with Abba J. 
Kastin, M.D., and Gurt A. Sandman, 
Ph.D., Miller demonstrated that MSH 
affected the brain wave patterns of 
rats (as measured by a electroen-
cephalogram or EEG) and that the 
hormone significantly increased per-
formance in these rats, particularly in 
behaviors where memory seemed to 
be involved. 
The researchers studied several 
possible explanations for these re-
sults and found that attention span 
was the key factor. "The reason the 
animals performed the way they did 
was that they were able to pay atten-
tion more easily and for longer peri-
ods of time. Hence, they learned bet-
ter, they remembered better and they 
performed better," said Miller. 
In a subsequent Mexico Gity study 
on humans. Miller and Kastin dem-
onstrated that MSH produced better 
performance results in the subjects 
during attentional tasks. That is, sub-
jects injected with synthetic alpha 
MSH performed reaction-time and 
visual-memory tasks significantly bet-
ter than they had prior to receiving 
the hormone. 
Miller duplicated these results in a 
more rigorous study conducted at 
Louisiana State University in 1971. In 
this study, though. Miller injected hu-
man subjects with synthetic MSH/ 
AGTH 4-10. 
Miller and his colleagues have 
since confirmed these findings in 
tests run on thousands of people. At 
Temple University Medical School in 
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Philadelphia, he conducted a study 
along with Gerald A. Groves, 
M.B.B.S., an assistant professor of 
psychiatry at BUSM, Michael J. 
Bopp, Ph.D., and Kastin on the influ-
ence of MSH/AGTH 4-10 on the cog-
nitive functioning of the elderly. The 
researchers found significant im-
provement in the the subjects' perfor-
mance in visual retention tests, 
though more pronounced in men 
than in women. 
Miller, who also is associate chair-
man for research of the Division of 
Psychiatry at BUSM, emphasizes 
that while this treatment can be ef-
fective in helping with concentration 
difficulties, it is not a cure-all for all 
physical and mental problems. "We 
(neuropeptide researchers) have 
come from a position of being dis-
missed in a cavalier kind of fashion 
to the point where neuropeptides are 
seen as the answers for everything. I 
think that assumption is as absurd as 
the original position," he said. 
Though the positive effects of the 
substance are well documented, 
some major problems remain to be 
solved before such a treatment can 
be made available for general use. 
For example, it now costs about 
$2,100 for an injection that produces 
a two- to three-hour improvement in 
concentration and, while no ill effects 
have been found with short-term use 
of the substance, researchers have 
yet to determine the effects of 
chronic synthetic MSH/AGTH 4-10 
use. 
To try to eliminate these problems. 
Miller now is studying the mecha-
nisms that liberate the MSH/AGTH 4-
Lyle H. Miller, Ph.D., examines laboratory 
data. (Photo by Bradford F. Herzog) 
10 fragment in the body. He hopes 
to discover ways of prompting the 
body to produce more of the sub-
stance, which would eliminate the 
need for injections of the costly syn-
thetic MSH/AGTH 4-10. 
Nicholas Gatsimpoolas, Ph.D., a 
research professor of psychiatry (bio-
chemistry) and a professor of bio-
chemistry; Louis J. Traficante, Ph.D., 
an associate research professor of 
psychiatry (biochemistry); and Ann L. 
Griffith, Ph.D., an assistant research 
professor of psychiatry (biochemis-
try), are among the other BUSM pro-
fessors in the Department of Biobe-
havioral Sciences involved in 
neuropeptide research. 
Miller hopes that the knowledge 
gained from current studies will be 
helpful in dealing with psychological 
disorders. "A poor attention span, or 
difficulty in concentrating, is a major 
symptom of a number of different 
kinds of psychopathology, such as 
depression or acute schizophrenic 
turmoil," he said. "If we could do 
something about that one aspect of 
psychopathology that runs across a 
number of catagories—that would be 
enough for me." 
— Paul D. Vaskas 
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